3Janse AJ, Gemke RJ, Uiterwaal CS,et al. Quality of life: patients and doctors dont always agree: a meta- analysis[ J]. J Clin Epidemiol, 2004,57:653 -661.
4Ware JE. SF-36 health survey update[J]. Spine, 2000,25:3130 -3139.
5Beaton DE, Schemitsch E. Measures of health - related quality of life and physical function [ J]. Clin Orthop Relat Res, 2003:90 -105.
6Garratt A, Sehmidt L, Mackintosh A,et al. Ouality of life measurement : bibliographic study of patient assessed health outcome measures [J]. BMJ, 2002,324:1417.
9Ware JE, Kosinski M. The SF -36 health survey (Version 2.0 ) technical note[ P]. Boston, MA : Health Assessment Lab, 1997.
10Ware JE, Sherbourne CD. The MOS 36 - item short - form health survey (SF- 36). Ⅰ. Conceptual framework and item selection[ J]. Med Care, 1992,30:473 - 483.
4Ware JE Jr, Snow KK, Kosinski M, et al.SF-36 health survey manual and interpretation guide.Boston: New England Medical Center the Health Institute,1993.1-12.
5Perneger TV, Leplege A, Etter JF,et al.Validation of a French-language version of the MOS 36-Item Short Form Health Survey(SF-36) in young healthy adults.J Clin Epidemiol, 1995,48:1051-1060.
6Guillemin F, Bombardier C, Beaton D.Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines.J Clin Epidemiol, 1993,46:1417-1432.
7Gandek B, Ware JE Jr.Methods for validating and norming translations of health status questionnaires: the IQOLA Project approach.International Quality of Life Assessment.J Clin Epidemiol, 1998,51:953-959.
9Lam CL, Gandek B, Ren XS, et al.Tests of scaling assumptions and construct validity of the Chinese(HK) version of the SF-36 Health Survey.J Clin Epidemiol, 1998,51:1139-1147.
10Ren XS, Amick B 3rd, Zhou L, et al.Translation and psychometric evaluation of a Chinese version of the SF-36 Health Survey in the United States.J Clin Epidemiol, 1998,51:1129-1138.
2Ostendorf M, van Stel HF, Buskens E, et al. Patient-reported outcome in total hip replacement : a comparison of five instruments of health status[J]. J Bone Joint Surg(Br) ,2004,86(10) :801 -808.
3Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent research and policy initiatives [ J ]. CA Cancer J Clin,2007,57(4) :278 -300.
4Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity[ J]. J Clin Oncol, 1998,16 ( 3 ) : 197 - 203.
5FDA. Guidance for industry: Skin irritation and sensitization testing of generic transdermal drug products [ J/OL ]. http ://www. Fda. gov,2000 - 03 - 02.
6Meyer PF, Gadsby PD, Van Sickle D, et al. Impedance-gradient electrode reduces skin irritation induced by transthoracic defibrillation [ J ]. Med Biol Eng Comput,2005,43 (3) :225 - 229.
7Hoekstra H J, Schraffordt-Koops H, Molenaar WM, et al. Results of isolated regional perfusion in the treatment of malignant soft tissue tumours of the extremities [ J ]. Cancer, 1987,60 (21) : 1703 - 1707.
8Hoven-Gondrie ML, Thijssens KM, Geertzen JH, et al. Isolated limb perfusion and external beam radiotherapy for soft tissue sarcomas of the extremity: long-term effects on normal tissue according to the LENT-SOMA scoring system [ J ]. Ann Surg Oncol, 2008,15 ( 5 ) : 1502 - 1510.
9Lejeune FJ, Pujol N, Lienard D, et al. Limb salvage by neoadjuvant isolated perfusion with TNFa and melphalan for non-resectable soft tissue sarcoma of the extremities [ J ]. Eur J Surg Oncol, 2000,26 (7) :669 -678.
10Eggermont AM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a muhicenter trial [ J]. J Clin Oncol, 1996, 14 (34) :2653 -2665.
